[Anti-VEGF treatment in age related macular degeneration].

Authors

Pauline Eymard

Published in

La Revue du praticien. Volume 76. Issue 7. Pages 703-706.

Abstract

Intravitreal anti-VEGF (Vascular Endothelial Growth Factor) injections have transformed the prognosis of exudative age-related macular degeneration (AMD) over the past two decades. They are effective in stabilizing the disease, despite the cost of regular injections and follow-up examinations. The advent of biosimilars and second-generation molecules (which allow for longer average treatment intervals) would help to reduce the cost of these therapies. While these treatments have significantly reduced visual impairment due to wet-AMD, they continue to represent a major economic challenge.

PMID:
42808622
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.